Charles River Laboratories

Titian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management Software

Retrieved on: 
Dienstag, Mai 28, 2024
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Other Science, Molecule, Partnership, Investment, Drug discovery, Associate, Therapy, Charles River Laboratories, Multimedia, Pharmaceutical industry

Titian Software and Charles River Laboratories have entered into a new 3-year partnership agreement, expanding Charles River’s sample management capabilities.

Key Points: 
  • Titian Software and Charles River Laboratories have entered into a new 3-year partnership agreement, expanding Charles River’s sample management capabilities.
  • This agreement aims to add significant new capabilities to Charles River’s sample management processes while providing a higher throughput capacity for automated liquid handling.
  • This ensures more efficient turnaround times, increased potential for assays performed, and quicker results, benefiting both Charles River and its customers.
  • Laboratory integrations are also a leading factor in the success and renewed partnership between Titian Software and Charles River.

SCbio's Life Science Accelerator, SCbioDrive, Launches Application for Inaugural Cohort

Retrieved on: 
Dienstag, Mai 7, 2024
Charles River Laboratories, Drive, Partnership, Research, Curriculum, Therapy, Science, Economic development, Multimedia, Palmetto, Organization, Growth, Management

Emerging therapeutics companies are invited to apply for the inaugural Fall 2024 program by June 28.

Key Points: 
  • Emerging therapeutics companies are invited to apply for the inaugural Fall 2024 program by June 28.
  • "The resources and knowledge that the SCbioDrive inaugural cohort will gain from the expert companies leading this curriculum will be invaluable," said SCbio President and CEO James Chappell.
  • Applications for the inaugural program cohort are available at www.scbio.org/scbiodrive .
  • SCbio is South Carolina's investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.

FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids

Retrieved on: 
Donnerstag, April 25, 2024
Conditional sentence, Cancer, Fibroblast, Communication, Trial of the century, Research, Degenerative disc disease, CDMO, Form, DNA, Therapy, Risk, Patient, Psoriasis, Charles River Laboratories, Multiple sclerosis, Wound healing, Drug discovery, Letter, Pharmaceutical industry

HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.

Key Points: 
  • HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.
  • To help advance FibroBiologics’ fibroblast-based therapies into the clinic, Charles River will conduct feasibility studies on FibroBiologics' cell manufacturing processes within its facility.
  • Additionally, contingent upon entering into a master services agreement, Charles River would serve as the contract development and manufacturing organization (CDMO) responsible for producing drug products for certain FibroBiologics’ clinical trials.
  • Combined with its legacy testing capabilities, Charles River offers a premier “concept-to-cure” advanced therapies solution.

Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial

Retrieved on: 
Dienstag, April 30, 2024
Health, Stem Cells, Clinical Trials, Pharmaceutical, Optical, Biotechnology, CLARA, Safety, MD, Patient, Eye, Physician, Charles River Laboratories, MBA, Clinical trial, Pharmaceutical industry

“Aurion Biotech is delighted that both enrollment and dosing in our Phase 1/2 trial are now complete, and that it happened more rapidly than we expected,” said Michael Goldstein, MD, MBA, President and Chief Medical Officer of Aurion Biotech.

Key Points: 
  • “Aurion Biotech is delighted that both enrollment and dosing in our Phase 1/2 trial are now complete, and that it happened more rapidly than we expected,” said Michael Goldstein, MD, MBA, President and Chief Medical Officer of Aurion Biotech.
  • The CLARA Phase 1 / 2 clinical trial is a prospective, multi-center, randomized, double masked, parallel-arm cell dose-ranging clinical trial in subjects with corneal edema secondary to corneal endothelial dysfunction.
  • The CLARA trial is designed to assess the safety, tolerability, and efficacy of AURN001 for the treatment of corneal edema secondary to corneal endothelial dysfunction.
  • Drug product for the CLARA trial was supplied by Aurion’s CDMO partner, Charles River Laboratories, from their production site in Memphis, TN.

Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

Retrieved on: 
Donnerstag, April 11, 2024
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Medical Devices, Research, Software, Artificial Intelligence, Science, Safety, Tissue, Doctor of Philosophy, Pathology, Marie Cassidy, Charles River Laboratories, MBA, Drug development, CRL, Drug discovery, WSI, Organization

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI.
  • In experimental and toxicologic pathology in particular, traditional light microscopic pathology methods can fall short of maintaining consistency and efficiency in analyzing histopathology data.
  • By augmenting evaluations with decision support technology, toxicologic pathologists have access to simple, visual tools to facilitate efficiency, consistency, and accuracy in their work.
  • Developed through a research collaboration between Charles River and Deciphex, Patholytix Foresight incorporates organ-based lesion classifiers created from an extensive data warehouse.

Healthcare Analytical Testing Services Market Worth $12.6 billion | MarketsandMarkets™

Retrieved on: 
Mittwoch, April 10, 2024
Merck Group, Pulse, Investment, Steris, ICON PLC, Parexel, Health care, Research, Sartorius AG, Wuxi, Intertek, Legal Entity Identifier, Labcorp, Region, Acquisition, Charles River Laboratories, SGS, Eurofins Scientific, INC, Market development

This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.

Key Points: 
  • This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.
  • This strategic acquisition strengthens SGS's presence in key market segments and enhances its ability to deliver comprehensive services to clients worldwide.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=108923833
    Healthcare Analytical Testing Services Market - Key Benefits of Buying the Report:
    This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.

Healthcare Analytical Testing Services Market Worth $12.6 billion | MarketsandMarkets™

Retrieved on: 
Mittwoch, April 10, 2024
Merck Group, Pulse, Investment, Steris, ICON PLC, Parexel, Health care, Research, Sartorius AG, Wuxi, Intertek, Legal Entity Identifier, Labcorp, Region, Acquisition, Charles River Laboratories, SGS, Eurofins Scientific, INC, Market development

This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.

Key Points: 
  • This collaboration aims to expedite clinical timelines, overcome analytical development barriers, and address regulatory hurdles associated with manufacturing and development processes.
  • This strategic acquisition strengthens SGS's presence in key market segments and enhances its ability to deliver comprehensive services to clients worldwide.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=108923833
    Healthcare Analytical Testing Services Market - Key Benefits of Buying the Report:
    This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the healthcare analytical testing services market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the healthcare analytical testing services market like Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), Element Materials Technology (UK) among others.

M-Files Leverages Automation and AI to Revolutionize the Workplace in 2023

Retrieved on: 
Donnerstag, März 7, 2024
Software, Technology, Artificial Intelligence, Data Management, Cloud, Acquisition, MENT, Collection, CRL, DocuSign, AI, ROI, Culture, Information Today, Growth, Charles River Laboratories, Microsoft Outlook, ARR, Centaur, Gold, Metadata, Business, Automation, Knowledge, Silver, Microsoft, Business intelligence, Information technology, Online shopping

“Automation is critical to ensure the productivity of knowledge workers,” said Antti Nivala, founder and CEO, M-Files.

Key Points: 
  • “Automation is critical to ensure the productivity of knowledge workers,” said Antti Nivala, founder and CEO, M-Files.
  • By creating a new work paradigm with knowledge work automation, we remove the challenge of sorting through information manually, simplifying daily tasks and increasing productivity.
  • In 2023 among the first in our market, M-Files enhanced its knowledge work automation platform with generative AI capabilities to revolutionize the way knowledge workers automate their processes - from document creation and management to workflow automation, external collaboration, enterprise search, security, compliance, and audit trails.
  • In 2023, M-Files expanded its offering with next-generation, no-code document automation capabilities through its acquisition of Ment and integration into the M-Files platform.

B&C and Acta Announce Appointment of Mark J. Washko as Senior Government Affairs Advisor, and Alexander E. Howard and Michelle C. Mims to Science Team Positions

Retrieved on: 
Freitag, März 1, 2024
National Association, Reno 1868 FC, Commerce, Molecular biology, Consultant, University, ASTM, House, Biophysical chemistry, Energy, EPA, Legislation, Public policy, Representative, Good laboratory practice, Advisory board, Committee, Environmental justice, Federation, College, Bowling Green State University, Quality assurance, Corteva, Majority, Biophysical environment, BASF, Environment, OECD, Business network, TSCA, Sunscreen Innovation Act, Charles River Laboratories, Government, Organization, GLP, Frank, Bachelor, Society, B&C, Policy, American Chemistry Council, Management

WASHINGTON, March 1, 2024 /PRNewswire-PRWeb/ -- Bergeson & Campbell, P.C. (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.

Key Points: 
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of Mark J. Washko, Alexander E. Howard, and Michelle C. Mims to key roles at our firms.
  • (B&C®) and The Acta Group (Acta®) are pleased to announce the appointment of several professionals to key roles at our firms.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.
  • Mr. Washko, Mr. Howard, and Ms. Mims join a powerful team of advocates, scientists, and regulatory and business consultants at B&C and Acta.

Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Retrieved on: 
Donnerstag, Februar 29, 2024
Investigational New Drug, CRL, Charles River Laboratories, LEAP, Entrepreneurship, OK, ATUM, Chemistry, CDMO, Safety, CHO, CGMP, Organization, Portable, Control, IND, CMC, Partnership, Pharmaceutical industry

The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.

Key Points: 
  • The collaboration is designed to enable a swift transition from pre-clinical stages directly to human clinical trials.
  • Combining Charles River's industry-leading experience in antibody discovery services, safety, and analytics with Wheeler's Portable CMC® platform will accelerate therapeutic discovery to Investigational New Drug (IND) submission timelines.
  • Wheeler Bio's mission is to solve translational challenges inherent in advancing from discovery to CMC development and early-clinical trial material supply.
  • Jesse McCool, CEO and Co-Founder of Wheeler Bio, stated, "Wheeler is excited to expand our relationship with Charles River and to link with their discovery organization.